The 2017 Bethesda System for Reporting Thyroid Cytopathology

Edmund S. Cibas, Syed Z Ali

Research output: Contribution to journalArticle

Abstract

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. The 2017 revision reaffirms that every thyroid FNA report should begin with 1 of 6 diagnostic categories, the names of which remain unchanged since they were first introduced: (1) Nondiagnostic or Unsatisfactory; (2) Benign; (3) Atypia of Undetermined Significance (AUS) or Follicular Lesion of Undetermined Significance (FLUS); (4) Follicular Neoplasm or Suspicious for a Follicular Neoplasm; (5) Suspicious for Malignancy; and (6) Malignant. There is a choice of two different names for some of the categories: a laboratory should choose the one it prefers and use it exclusively for that category; synonymous terms (eg, AUS and FLUS) should not be used to denote 2 distinct interpretations. Each category has an implied cancer risk that ranges from 0% to 3% for the "Benign" category to virtually 100% for the "Malignant" category, and, in the 2017 revision, the malignancy risks have been updated based on new (post 2010) data. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. The recent reclassification of some thyroid neoplasms as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has implications for the risk of malignancy, and this is accounted for with regard to diagnostic criteria and optional notes. Such notes can be useful in helping guide surgical management.

Original languageEnglish (US)
JournalJournal of the American Society of Cytopathology
DOIs
StateAccepted/In press - 2017

Fingerprint

Thyroid Gland
Neoplasms
Fine Needle Biopsy
Thyroid Neoplasms
Names

Keywords

  • Bethesda
  • Cytopathology
  • Fine-needle aspiration
  • Molecular testing
  • Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)
  • Terminology
  • Thyroid

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The 2017 Bethesda System for Reporting Thyroid Cytopathology. / Cibas, Edmund S.; Ali, Syed Z.

In: Journal of the American Society of Cytopathology, 2017.

Research output: Contribution to journalArticle

@article{48d21954d1db4fa2a210e8fc2cfc61ec,
title = "The 2017 Bethesda System for Reporting Thyroid Cytopathology",
abstract = "The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. The 2017 revision reaffirms that every thyroid FNA report should begin with 1 of 6 diagnostic categories, the names of which remain unchanged since they were first introduced: (1) Nondiagnostic or Unsatisfactory; (2) Benign; (3) Atypia of Undetermined Significance (AUS) or Follicular Lesion of Undetermined Significance (FLUS); (4) Follicular Neoplasm or Suspicious for a Follicular Neoplasm; (5) Suspicious for Malignancy; and (6) Malignant. There is a choice of two different names for some of the categories: a laboratory should choose the one it prefers and use it exclusively for that category; synonymous terms (eg, AUS and FLUS) should not be used to denote 2 distinct interpretations. Each category has an implied cancer risk that ranges from 0{\%} to 3{\%} for the {"}Benign{"} category to virtually 100{\%} for the {"}Malignant{"} category, and, in the 2017 revision, the malignancy risks have been updated based on new (post 2010) data. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. The recent reclassification of some thyroid neoplasms as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has implications for the risk of malignancy, and this is accounted for with regard to diagnostic criteria and optional notes. Such notes can be useful in helping guide surgical management.",
keywords = "Bethesda, Cytopathology, Fine-needle aspiration, Molecular testing, Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), Terminology, Thyroid",
author = "Cibas, {Edmund S.} and Ali, {Syed Z}",
year = "2017",
doi = "10.1016/j.jasc.2017.09.002",
language = "English (US)",
journal = "Journal of the American Society of Cytopathology",
issn = "2213-2945",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - The 2017 Bethesda System for Reporting Thyroid Cytopathology

AU - Cibas, Edmund S.

AU - Ali, Syed Z

PY - 2017

Y1 - 2017

N2 - The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. The 2017 revision reaffirms that every thyroid FNA report should begin with 1 of 6 diagnostic categories, the names of which remain unchanged since they were first introduced: (1) Nondiagnostic or Unsatisfactory; (2) Benign; (3) Atypia of Undetermined Significance (AUS) or Follicular Lesion of Undetermined Significance (FLUS); (4) Follicular Neoplasm or Suspicious for a Follicular Neoplasm; (5) Suspicious for Malignancy; and (6) Malignant. There is a choice of two different names for some of the categories: a laboratory should choose the one it prefers and use it exclusively for that category; synonymous terms (eg, AUS and FLUS) should not be used to denote 2 distinct interpretations. Each category has an implied cancer risk that ranges from 0% to 3% for the "Benign" category to virtually 100% for the "Malignant" category, and, in the 2017 revision, the malignancy risks have been updated based on new (post 2010) data. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. The recent reclassification of some thyroid neoplasms as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has implications for the risk of malignancy, and this is accounted for with regard to diagnostic criteria and optional notes. Such notes can be useful in helping guide surgical management.

AB - The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. The 2017 revision reaffirms that every thyroid FNA report should begin with 1 of 6 diagnostic categories, the names of which remain unchanged since they were first introduced: (1) Nondiagnostic or Unsatisfactory; (2) Benign; (3) Atypia of Undetermined Significance (AUS) or Follicular Lesion of Undetermined Significance (FLUS); (4) Follicular Neoplasm or Suspicious for a Follicular Neoplasm; (5) Suspicious for Malignancy; and (6) Malignant. There is a choice of two different names for some of the categories: a laboratory should choose the one it prefers and use it exclusively for that category; synonymous terms (eg, AUS and FLUS) should not be used to denote 2 distinct interpretations. Each category has an implied cancer risk that ranges from 0% to 3% for the "Benign" category to virtually 100% for the "Malignant" category, and, in the 2017 revision, the malignancy risks have been updated based on new (post 2010) data. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. The recent reclassification of some thyroid neoplasms as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has implications for the risk of malignancy, and this is accounted for with regard to diagnostic criteria and optional notes. Such notes can be useful in helping guide surgical management.

KW - Bethesda

KW - Cytopathology

KW - Fine-needle aspiration

KW - Molecular testing

KW - Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)

KW - Terminology

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=85029485270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029485270&partnerID=8YFLogxK

U2 - 10.1016/j.jasc.2017.09.002

DO - 10.1016/j.jasc.2017.09.002

M3 - Article

C2 - 31043290

AN - SCOPUS:85029485270

JO - Journal of the American Society of Cytopathology

JF - Journal of the American Society of Cytopathology

SN - 2213-2945

ER -